Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Contemp Clin Trials. 2020 Jan 22;90:105938. doi: 10.1016/j.cct.2020.105938

Figure 1.

Figure 1.

Study schematic for the trial “Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: a randomized, open-label, controlled phase 3 clinical trial (S31/A5349)”

Note. R=rifampin, H=isoniazid, Z=pyrazinamide, E=ethambutol, P=rifapentine, M=moxifloxacin.